fedratinib (Inrebic) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Fedratinib (SAR-302503, TG-101348) is a selective small-molecule inhibitor of Janus kinase-2. Fedratinib demonstrated therapeutic efficacy in a murine model of myeloproliferative disease. Sanofi was developing Fedratinib for the treatment of myeloproliferative diseases and solid tumors. The clinical development of fedratinib was terminated after reports of Wernicke's encephalopathy in myelofibrosis patients.   NCATS

Chemistry

  • SMILES: CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC4=CC=CC(=C4)S(=O)(=O)NC(C)(C)C
  • InChIKey: JOOXLOJCABQBSG-UHFFFAOYSA-N
  • Mol. Mass: 524.678
  • ALogP: 4.82
  • ChEMBL Molecules:
    fedratinib  
    fedratinib hydrochloride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$128.0081 - $167.0854
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

fedratinib | n-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino) pyrimidin-4-ylamino)benzenesulfonamide | sar302503 | sar-302503 | tg101348 | tg-101348

Organizations (14)

Research & Development (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (1)


 

Primary Myelofibrosis (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Arthritis, Rheumatoid (Phase 3)

Dermatomyositis (Phase 4)

Healthy Volunteers (Phase 1)

Hematologic Neoplasms (Phase 3)

Kidney Failure, Chronic (Phase 1)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Neutrophilic, Chronic (Phase 2)

Liver Diseases (Phase 1)

Mutation (Phase 1)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasms (Phase 1)

Polycythemia Vera (Phase 3)

Primary Myelofibrosis (Phase 3)

Thrombocythemia, Essential (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial Organizations: 13

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue